title: [Pathogenetic substantiation of using peptidases in the treatment of patients with generalized periodontitis].
abstract: 76 patients of whom 52 patients with GP-II degree exacerbative and 24 somatically healthy people aged 20-50 years were studied. Based on these immunological examination serapeptydase was assigned per os, as a complementary product to the basic therapy. Any concentration of secretory leukocyte protease inhibitor (SLPI) indicates the dominant hyperergic inflammation in periodontal tissues, accompanied by increased proteolysis. Profitable accumulation in the serum of patients with GP inhibitors proteinase to 53%, IL-1beta - to 26.3%, IL-2 - to 19.5%, IL-8 - to 42.8% FNPalpha - up to 48.3%, and reduction of IFNalpha to 78.1% indicates changes of complex "protease-antiproteases" immunocompetent cells and activation of inflammatory processes at the local and systemic levels.
authors.forename: I Ie
authors.initials: IIe
authors.lastname: Serheieva
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D055113:Chronic Periodontitis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000097:blood* / Q000276:immunology; D003627:Data Interpretation, Statistical; D005260:Female; D005883:Gingival Crevicular Fluid / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000008:administration & dosage / Q000627:therapeutic use*; D012469:Salivary Glands / Q000187:drug effects / Q000276:immunology; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000097:blood*; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; D010447:Peptide Hydrolases; C022640:serratiopeptidase